Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients
Kesavan, M.; Meyrick, D.; Gallyamov, M.; Turner, J.H.; Yeo, S.; Cardaci, G.; Lenzo, N.P. Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients. Diagnostics 2021, 11, 515. https://doi.org/10.3390/diagnostics11030515
Kesavan M, Meyrick D, Gallyamov M, Turner JH, Yeo S, Cardaci G, Lenzo NP. Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients. Diagnostics. 2021; 11(3):515. https://doi.org/10.3390/diagnostics11030515
Chicago/Turabian StyleKesavan, Murali, Danielle Meyrick, Marat Gallyamov, J. H. Turner, Sharon Yeo, Giuseppe Cardaci, and Nat P. Lenzo. 2021. "Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients" Diagnostics 11, no. 3: 515. https://doi.org/10.3390/diagnostics11030515